Crinetics Pharmaceuticals, Inc. - Special Call Transcript
Ladies and gentlemen, thank you for standing by, and welcome to the Crinetics Pharmaceuticals ACROBAT EDGE Phase II Interim Results and Corporate Update Conference Call. (Operator Instructions)
I would now like to hand the conference over to your speaker, Robert Uhl. Please go ahead.
Thank you, operator. Good morning, everyone, and welcome to Crinetics Pharmaceuticals conference call to provide interim results from the ACROBAT EDGE Phase II clinical trial of once-daily oral paltusotine for the treatment of acromegaly. The company will also provide a corporate update.
Before we begin, I'd like to let you know that on this call, the Crinetics team will reference data that are presented on a set of slides that you can access from the Investor Calendar events page of the Crinetics website. The interim data from the ACROBAT EDGE trial is also contained in the news release from yesterday afternoon. Joining me on the call from Crinetics are Scott Struthers, Founder and Chief Executive Officer; and Alan
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |